Current AD diagnostics rely on cerebrospinal fluid (CSF) biomarkers such as Aβ42/40, total tau, and phosphorylated tau, together with cognitive assessments and neuroimaging including positron emission tomography (PET) and CT. This evidence concerns the gene MAPT and Alzheimer disease.